Please use this identifier to cite or link to this item:
Title: Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy.
Austin Authors: Jandeleit-Dahm, K;Cao, Zemin;Cox, Allison J;Kelly, D J;Gilbert, Richard E;Cooper, Mark E
Affiliation: Department of Medicine, University of Melbourne, Austin, Victoria, Australia
Issue Date: 1-Jul-1999
Publication information: Kidney International. Supplement; 71(): S31-6
Abstract: It has been suggested that lipids promote renal injury and that 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors confer renoprotection in certain renal diseases, including diabetic nephropathy.Sprague-Dawley rats were randomized to sham, subtotal nephrectomy (STNx) or STNx + atorvastatin groups. After 12 weeks, proteinuria, renal function, glomerular injury, renal transforming growth factor-beta (TGF-beta) gene expression and macrophage (ED1-positive cells) accumulation were assessed. In addition, the effects of HMG CoA reductase in human diabetic nephropathy were reviewed.Atorvastatin therapy was associated with a modest reduction in proteinuria and glomerulosclerosis without influencing lipid levels or renal function in STNx rats. These effects were associated with decreased renal TGF-beta 1 gene expression and less glomerular and tubulointerstitial macrophage accumulation. The renoprotective effects of HMG CoA reductase inhibitors in both insulin- and non-insulin-dependent diabetic subjects with either incipient or overt nephropathy appear to be highly variable.HMG CoA reductase inhibition appears to confer renoprotection via effects on prosclerotic cytokines such as TGF-beta and macrophage accumulation, independent of their lipid-lowering properties. The role of lipid-lowering agents in early or overt diabetic nephropathy remains to be fully ascertained.
Gov't Doc #: 10412733
Journal: Kidney International. Supplement
Type: Journal Article
Subjects: Animals
Anticholesteremic Agents.therapeutic use
Clinical Trials as Topic
Diabetic Nephropathies.drug therapy
Disease Progression
Gene Expression.drug effects
Heptanoic Acids.therapeutic use
Hydroxymethylglutaryl-CoA Reductase Inhibitors.therapeutic use
In Situ Hybridization
Kidney Diseases.drug therapy.pathology.physiopathology
Kidney Glomerulus.drug effects.metabolism.pathology
Lovastatin.therapeutic use
Pravastatin.therapeutic use
Pyrroles.therapeutic use
Rats, Sprague-Dawley
Simvastatin.therapeutic use
Transforming Growth Factor beta.genetics
Appears in Collections:Journal articles

Show full item record

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.